⚙️ ICYMI: Investing in the AI revolution

Plus, how to retire with riches | [Finimize](   TOGETHER WITH     In Case You Missed It… World-changing technologies go through life just like the rest of us. They start as seedlings, then optimistic babies, troublesome toddlers – and they can end up as exhausted, retired ideas. So let’s find out how to invest along the journey, and how to prepare for your own golden years, too. [AI And Investing In The New Technological Revolution]( Huge-scale fundamental transitions can be tumultuous – but profitable. So it’s worth checking out their historical patterns, to see what we can learn about the current one. [Check out the different stages of investing in disruptive trends.]( [Three Questions To Put You On The Path Toward A Retirement Bliss]( Your post-work life may seem like a long way off (or it might be rushing at you). Whatever your timeline, Theodora’s got a simple guide to help you keep your goals in sight. [Find out how to retire on a bed of cash… figuratively, of course.]( SPONSORED BY BIOSTEM The future of regenerative medicine [Biostem’s (BSEM)]( COO left the military to explore treatments for his father in radiation therapy. He focused on [regenerative medicine]( using material from human umbilical cords to restore tissue or organ damage. And when his father regained his speech and motor skills, [BSEM]( was founded. The company uses [regenerative tissue therapies]( to create allografts and was recently awarded a [Q code]( a certification that means the treatments can be [reimbursed by Medicare](. With that sort of innovation, it's no wonder [Zacks]( just upgraded Biostem's [stock price target to $18.70](. [Find Out More]( *See disclosures below. When you support our sponsors, you support us. Thanks for that. If you want your brand featured here, [get in touch.]( [Four Spots Where JPMorgan Private Bank Sees Opportunities]( The wealth manager is sticking with its key themes for 2024. So Russell dove in to find ways that you can take advantage. [See the areas that have piqued JPMorgan’s interest.]( [IPOs Are Back, Baby (And Not Just In The US)]( It’s been a quiet time for stock debuts, but Swiss skincare brand Galderma has just given the market a lift. And Carl says you might want to give it a second look. [Discover the companies that are lighting up the public market.]( SPONSORED BY BIOSTEM This could be your way into a $18 billion medical market – no PhD required [BSEM’s net revenue is over 200% higher]( than a year ago, and a collection of highly regarded [partners and regulatory sign-offs]( have enforced its credibility. [BSEM]( stands to make up a massive part of the global stem cell market, which is predicted to be worth [$18 billion by 2028](. And above all, it stands to improve a lot of lives. [Discover More]( *See disclosures below. When you support our sponsors, you support us. Thanks for that. If you want your brand featured here, [get in touch.]( 🎙 Finimize Live [Building Wealthy Women: Investing in Your Future]( [Building Wealthy Women: Investing in Your Future]( Women are still paid less than men, leaving them with less free cash to invest and a smaller retirement pot as a result. We’re not having that, so our event with CFA Institute is designed to help you take back the control. Global • Thu, Apr 11th [Get Tickets]( IMPORTANT DISCLOSURES *This content is for US investors only, if you are not a US investor please ignore this content. This content is a paid advertisement for BioStem (OTC:BSEM) from Sideways Frequency and Finimize. This is not Finimize editorial content. Finimize received a fixed fee for producing, hosting and promoting this content on behalf of BioStem (OTC:BSEM), totalling $15,000. Other than the compensation received for this service, Finimize and its principals are not affiliated with either Sideways Frequency or BioStem (OTC:BSEM). Finimize and its principals have no ownership in BioStem (OTC:BSEM). The content on this page should not be taken as advice, an endorsement, or a recommendation from Finimize and its principals to buy or sell any security. Finimize and its principals have not evaluated the accuracy of any claims made on this page. Finimize and its principals recommend that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky and capital is at risk. Past performance is not indicative of future results. You stay classy, {NAME} 😉 [Turn off these emails]( or [unsubscribe]( from all Finimize Emails including the Daily Brief. Crafted by Finimize Ltd. | 280 Bishopsgate, London, EC2M 4AG [View in browser](